Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab
Matthew Ku, Geoff Chong, Eliza A Hawkes
BLOOD REVIEWS | CHURCHILL LIVINGSTONE | Published : 2017
Recent proliferation of novel targeted therapies in lymphoma has been substantial. B-cell receptor pathway inhibitors and immune checkpoint inhibitors have been a major focus, however significant advances in monoclonal antibodies (MoAbs) which directly target malignant cells have also occurred. These MoAbs continue to make significant impact in lymphoma management. Novel dosing schedules of anti-CD20 MoAb rituximab potentially optimise efficacy in specific lymphoma subgroups, as certain populations may be receiving suboptimal doses using current schedules. Next-generation anti-CD20 MoAbs may surpass rituximab in terms of efficacy. MoAbs targeting other B-cell surface antigens and antibody-dr..View full abstract
No study sponsor was involved in the writing of this manuscript. Dr. Matthew Ku has no disclosures. Dr. Geoff Chong received research funding from Novartis, Pharmacyclics, Merck KGaA, and Bayer. Dr. Eliza Hawkes received travel expenses from Takeda.